Streamlining Cigna Verzenio Prior Authorization

Navigating Verzenio Prior Authorization with Cigna Healthcare and Evernorth

Verzenio, an oral CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer, often requires prior authorization due to its specialty status and cost. For Cigna Healthcare members, this process involves distinct pathways depending on the benefit. Klivira's automation platform integrates with both medical and pharmacy benefit channels to streamline these submissions.

Submission Channels for Cigna Verzenio Prior Authorization

Cigna Healthcare leverages different channels for prior authorization based on the benefit. For Verzenio, which is typically covered under the pharmacy benefit, submissions are primarily handled by Evernorth's Express Scripts, with Accredo Specialty Pharmacy managing fulfillment. Medical benefit exceptions or associated services may route through CignaforHCP.com.

Key Submission Pathways for Verzenio

• **Pharmacy Benefit (Express Scripts/Accredo):** Submissions for Verzenio route through Evernorth's Express Scripts provider PA system, leveraging ePA partners like CoverMyMeds and Surescripts for prescriber-initiated workflows. Accredo handles specialty pharmacy fulfillment.
• **Medical Benefit (CignaforHCP.com):** While less common for oral oncology drugs, medical benefit PAs for Cigna Healthcare are submitted via the CignaforHCP.com provider portal or X12 278 transactions through clearinghouses.
• **Policy Access:** Cigna Healthcare publishes coverage policies and medical-necessity guidelines, often referencing NCCN Compendium for oncology drugs, on its public provider site.

Common Denial Reasons and Appeal Pathways for Verzenio

Denials for Verzenio PA under Cigna Healthcare often stem from insufficient clinical documentation, failure to meet step therapy requirements, or non-formulary issues with Express Scripts. Klivira's platform helps identify potential issues pre-submission.

Typical Denial Categories and Resolution

• **Medical Necessity:** Incomplete documentation demonstrating NCCN-compendium-supported clinical indications or insufficient trial of preceding therapies.
• **Step Therapy:** Failure to document adherence to Cigna/Express Scripts' required sequence of treatments.
• **Non-Formulary:** Issues related to the specific Verzenio formulation or quantity limits not aligning with the Express Scripts formulary.
• **Appeal Process:** Cigna Healthcare offers peer-to-peer reviews for clinical denials and a structured appeal process documented on CignaforHCP.com and in the Cigna Provider Manual.

Leveraging Electronic PA (ePA) for Verzenio with Cigna and Evernorth

Cigna Healthcare participates in the HL7 Da Vinci Project ecosystem, and Evernorth's Express Scripts has long-established electronic prior authorization capabilities. These ePA channels are critical for accelerating Verzenio approvals.

ePA Capabilities and Regulatory Impact

• **Express Scripts ePA:** Electronic submissions via CoverMyMeds and Surescripts are widely used for pharmacy benefit drugs like Verzenio, facilitating rapid data exchange.
• **Da Vinci Project:** Cigna's engagement with Da Vinci standards (PAS, CRD, DTR) indicates a strategic move towards more integrated, real-time PA processes, enhancing future automation potential.
• **CMS-0057-F Impact:** For Medicare Advantage plans, Cigna is subject to the CMS-0057-F rule, mandating faster PA turnaround times (72-hour standard, 24-hour expedited), emphasizing the need for robust ePA.

Klivira's Role in Optimizing Cigna Verzenio PA Workflows

Klivira's platform automates the end-to-end prior authorization process for Verzenio, integrating directly with EMRs and connecting to Cigna Healthcare's CignaforHCP portal and Evernorth's Express Scripts ePA channels. This reduces manual effort, improves submission quality, and accelerates patient access to critical oncology medications.